NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Phibro Animal Health Corp is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Phibro Animal Health develops and markets animal health products and mineral nutrition supplements across multiple countries. The company serves livestock producers, farmers and veterinarians through direct sales and distribution networks, offering antibacterials, anticoccidials, vaccines and nutritional products for poultry, cattle, swine and aquaculture. Its segments comprise Animal Health, Mineral Nutrition, and Performance Products for industrial applications.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Phibro Animal Health Corp stock.
Undervalued: intrinsic value $69.27 per share, market price $34.92, margin of safety 49.6% (as of 2026-11-17).
Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $69.27; the price of $34.92 is 50% below that value, and 83% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
PAHC is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 7.1% (average of 3 methods) values the shares at $69.27; the price of $34.92 is 50% below that value, and 83% of that value comes from beyond year five.
$69.27 per share (as of the 2026-11-17 close), against a market price of $34.92. That is a margin of safety of 49.6%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.